Matthew Herper

AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He’d like it to be higher.

RFK Jr.'s unilateral decision to revise Covid booster guidance represents a bulldozing of safeguards, our columnist writes

ASCO and Google Cloud's AI tool is meant to help oncologists query just its trusted cancer treatment guidelines, without extraneous information.

Vinay Prasad will be the next director of the FDA's Center for Biologics Evaluation and Research, after Peter Marks was forced out.

A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two — and, therefore, also helps to prevent cancer.

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity.

Trump's health secretary told FDA workers that tackling childhood chronic diseases should be the agency's chief priority.

A former top FDA official said it’s only a matter of time before the chaos at the agency starts to impact drug reviews. 

Why the ouster of Peter Marks, a senior FDA official, is a huge deal, whether you liked him or not.

Deputy directors at the FDA center that oversees the regulation of cancer drugs plan to leave, adding to a flood of top talent in recent months.